Levacetylleucine

Levacetylleucine (N-acetyl-L-leucine), an orally bioavailable and brain-penetrant compound, is an acetylated derivative of amino acid Leucine. Levacetylleucine is the active form of N-acetyl-leucine (NAL) . Levacetylleucine attenuates neuronal death and neuroinflammation in the cortical tissue of mice. Levacetylleucine also potentially improves ameliorates lysosomal and metabolic dysfunction. Levacetylleucine improves compensation of postural symptoms after unilateral chemical labyrinthectomy (UL) in rats. Levacetylleucine is promising for research of neurological manifestations of Niemann-Pick disease type C, traumatic brain injury and neurodegeneration prevention[1][2][3][4].

Product Specifications

CAS Number

[1188-21-2]

Product Name Alternative

N-Acetyl-L-leucine

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Amino Acid Derivatives

Type

Natural Products

Related Pathways

Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/n-acetyl-l-leucine.html

Purity

98.0

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C)C[C@H](NC(C)=O)C(O)=O

Molecular Formula

C8H15NO3

Molecular Weight

173.21

Precautions

H302, H315, H319, H335

References & Citations

[1]Bremova-Ertl T, et al. Trial of N-Acetyl-l-Leucine in Niemann-Pick Disease Type C[J]. N Engl J Med. 2024 Feb 1;390 (5) :421-431. |[2]Sarkar C, et al. N-acetyl-L-leucine: a promising treatment option for traumatic brain injury[J]. Neural Regen Res. 2022 Sep;17 (9) :1957-1958. |[3]Günther L, et al. N-acetyl-L-leucine accelerates vestibular compensation after unilateral labyrinthectomy by action in the cerebellum and thalamus[J]. PLoS One. 2015 Mar 24;10 (3) :e0120891.|[4]Hegdekar N, et al. N-Acetyl-L-leucine improves functional recovery and attenuates cortical cell death and neuroinflammation after traumatic brain injury in mice[J]. Sci Rep. 2021 Apr 29;11 (1) :9249.